US EditionRoche's Obesity Drug Helps Almost 87% People Lose At Least 10% Weight - Roche Holding (OTC:RHHBY)
CT-388 showed a strong dose-response with 95.7% of participants losing over 5% body weight and 26.1% losing over 30% at 48 weeks, with mostly mild gastrointestinal side effects.
- On Tuesday, Roche Holdings AG released topline CT388-103 Phase 2 results showing CT-388 at 24 mg achieved placebo-adjusted weight loss of 22.5% at 48 weeks with no plateau.
- Following its Carmot deal, Roche positioned CT-388 as a priority asset, designating it fast-track and accelerating development for a Phase 3 programme expected this quarter.
- Trial data show strong responder rates at week 48 for the 24 mg dose, with 95.7% exceeding 5% weight loss and mainly mild-to-moderate gastrointestinal adverse events; discontinuation rates were 5.9% study drug versus 1.3% placebo.
- More than half of CT-388 recipients saw BMI fall below 30 kg/m2, and Roche will present full study results at an upcoming medical meeting while exploring combination with petrelintide.
- While CT-388 looks competitive with existing dual agonists, late-stage and novel entrants are accelerating as retatrutide recently showed up to 28.7% weight loss and oral rivals could arrive in the coming weeks.
15 Articles
15 Articles
Roche Obesity Drug’s Phase 2 Results Are Competitive, But True Test May Come From Combo Studies
Preliminary Phase 2 data show Roche’s CT-388 led to a 22.5% placebo-adjusted weight loss measured at 48 weeks. Based on these results, the pharmaceutical company plans to advance the GLP-1 and GIP agonist to a Phase 3 clinical trial in obesity. The post Roche Obesity Drug’s Phase 2 Results Are Competitive, But True Test May Come From Combo Studies appeared first on MedCity News.
The company paved the way in the fight against obesity drugs with robust results from the mid-phase clinical trial of CT-388 and is moving towards the start of its late-phase study.
Roche moves obesity drug to pivotal trials after mid-stage success
Roche plans to launch Phase 3 studies of its leading obesity candidate this quarter after reporting Tuesday that the drug led to significant weight loss in a mid-stage trial. The drug, known as CT-388, led to a placebo-adjusted weight loss of 18.3% after 48 weeks in the Phase 2 trial at the highest dose tested of 24 milligrams, the Swiss pharma said. Roche said that patients were still losing weight at the end of the study period. Just under 6%…
Roche's Obesity Drug Helps Almost 87% People Lose At Least 10% Weight - Roche Holding (OTC:RHHBY)
Roche Holdings AG (OTC:RHHBY) on Tuesday released topline results from the CT388-103 Phase 2 trial of CT-388 for obesity. CT-388 is an investigational once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist being developed for the treatment of obesity, type 2 diabetes, and other obesity-related comorbidities. Trial Data The 469-patient trial was designed to evaluate the efficacy and safety of CT-388 at low, middle, and high doses. I…
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity
A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p 54% of participants on the 24 mg dose achieved...
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
